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PharmacologyThe success of pharmacological treatments in primary liver cancers is limited by the marked efﬁcacy of
mechanisms of chemoresistance already present in hepatocytes. The role of the nuclear receptor FXR is unclear.
Although, in non-treated liver tumors, its expression is reduced, the refractoriness to anticancer drugs is high.
Moreover, the treatment with cisplatin up-regulates FXR. The aim of this study was to investigate whether
FXR is involved in stimulating chemoprotection/chemoresistance in healthy and tumor liver cells. In human
hepatocytes, the activation of FXR with the agonist GW4064 resulted in a signiﬁcant protection against
cisplatin-induced toxicity. In human hepatoma Alexander cells, with negligible endogenous expression of
FXR, GW4064 also protected against cisplatin-induced toxicity, but only if they were previously transfected
with FXR/RXR. Investigation of 109 genes potentially involved in chemoresistance revealed that only ABCB4,
TCEA2, CCL14, CCL15 and KRT13 were up-regulated by FXR activation both in human hepatocytes and FXR/
RXR-expressing hepatoma cells. In both models, cisplatin, even in the absence of FXR agonists, such as bile
acids and GW4064, was able to up-regulate FXR targets genes, which was due to FXR-mediated trans-
activation of response elements in the promoter region. FXR-dependent chemoprotection was also efﬁcient
against other DNA-damaging compounds, such as doxorubicin, mitomycin C and potassium dichromate, but
not against non-genotoxic drugs, such as colchicine, paclitaxel, acetaminophen, artesunate and sorafenib. In
conclusion, ligand-dependent and independent activation of FXR stimulates mechanisms able to enhance the
chemoprotection of hepatocytes against genotoxic compounds and to reduce the response of liver tumor cells
to certain pharmacological treatments.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the third cause of cancer-
related death worldwide. Surgery is the curative therapy of choice,
but the resection of these tumors is not always possible. The use of
pharmacological approaches is limited because, owing to the marked
drug refractoriness of these tumors, the response to available adjuvant
chemotherapy is very poor. This characteristic depends in part on
the expression of the genes involved in a variety of mechanisms of
chemoresistance (MOC), which are also involved in the chemoprotection
of normal liver tissue. These include a reduction in drug/toxin uptake
(MOC-1a), an enhanced drug/toxin export (MOC-1b), a reductionpatocellular carcinoma; MOC,
or; TLDA, Taqman low density
and Pharmacology, University
37007-Salamanca, Spain. Tel.:
l rights reserved.in metabolic pro-drug/toxin activation or an increase in drug/toxin inac-
tivation (MOC-2), changes in molecular targets (MOC-3), enhanced
DNA repair (MOC-4), and a modiﬁcation in the pro-apoptotic
(MOC-5a) versus pro-survival (MOC-5b) balance [1].
The farnesoid X receptor (FXR, gene symbol NR1H4) is a transcription
factormainly expressed in the liver, intestine, kidney, and adrenal glands.
To activate the expression of its target genes, FXR heterodimerizes
with the retinoid X receptor α (RXRα) and, upon activation by speciﬁc
agonists, binds to FXR response elements (FXREs), mainly IR-1 (inverted
repeats separated by 1 nucleotide) [2].
FXR has traditionally been considered as a speciﬁc bile acid recep-
tor involved in the control of bile acid homeostasis. However, a role of
FXR in the control of lipid and glucose metabolism has been described
[3], and more recently, FXR has also been implicated in the preven-
tion of hepatic and intestinal carcinogenesis [4,5], liver regeneration
[6], the barrier function of the intestine [7], attenuation of the adverse
effects of cholestasis [8] and the prevention of gallstone formation [9].
To carry out some of these functions, FXR regulates the expression of
genes involved in MOC, such as phase I oxidation enzymes (CYP3A4)
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phase III transporters (BSEP andMDR3) [13,14]. This implies a potential
role of FXR in the hepatic handling of potentially toxic xenobiotics, such
as acetaminophen [15]. Moreover, we have recently described a role for
FXR in chemoresistance to cisplatin in colon cancer cells [16].
Nevertheless, the role of FXR in the control of the genes involved
in MOC remains unclear. Although, in non-treated liver tumors, the
FXR expression is reduced, the refractoriness to antitumor drugs is
high [17]. Moreover, some of them, such as cisplatin, are able to
induce FXR expression in tumor cells [17]. Therefore, the aim of this
study was to investigate whether FXR is involved in the activation
of chemoprotection in healthy hepatocytes and liver cancer cells.
2. Materials and methods
2.1. Chemicals
Acetaminophen, cisplatin, colchicine, doxorubicin, mitomycin C, pac-
litaxel and potassium dichromate were obtained from Sigma-Aldrich
(Madrid, Spain). GW4064 was obtained from Santa Cruz Biotechnology
(Heidelberg, Germany). Sorafenib tosylate was obtained through
the Pharmacy Department, University Hospital (Salamanca, Spain).
Artesunate was kindly provided by Dr. Thomas Effert (University of
Mainz, Germany). The purity of all these compounds was ≥97%. All
other chemicals were of analytical grade.
2.2. Cloning
FXRα1(−) isoform (containing exons 1 to 3 and a 12-bp deletion
in exon 5) [18] and RXRα, henceforth designated simply as FXR and
RXR, were cloned using Gateway technology. The coding sequences
were ampliﬁed by PCR using DNA from HepG2 cells and Jeg-3 cells,
respectively, and the high ﬁdelity AccuPrime Pfx DNA polymerase
and gene speciﬁc primers (Supplementary Table 1) with appropriate
attB adapters. The attB-ﬂanked PCR products were recombined with
the attP-containing pDONR207 vector (Invitrogen, Barcelona, Spain)
to generate Entry plasmids, which were further recombined with
the pcDNA6.2-V5 Destination vector (Invitrogen), to generate the
Expression vectors. The pGL4.28[Luc2CP] vector (Promega, Madrid,
Spain) was used to obtain pGL4.28[Luc2CP]/IR-1, containing the con-
sensus IR-1 response element for FXR. The IR-1 (AGGTCAATGACCT)
consisted of an inverted repeat of the consensus sequence AGGTCA sep-
arated by one nucleotide (A) [2]. The exact nucleotide sequence of all
constructs was conﬁrmed by gel-electrophoresis-based sequencing.
2.3. Cell culture and transfection assays
Human hepatoma Alexander cells (PLC/PRF/5, ATCC: CRL-8024),
human hepatocellular carcinoma SK-Hep-1 cells (ATCC: HTB-52) and
human hepatoblastoma HepG2 cells (ATCC: HB-8065) were provided
by LGC Standards S.L.U., Barcelona (Spain) and cultured as recommended
by the supplier. Human hepatocytes were isolated from the healthy liver
tissue obtained by surgical resections of primary or secondary liver
tumors after written consent of the patients (4 men, 2 women, 59 ±
5.3 years) at the Reina Soﬁa Hospital (Cordoba, Spain). Hepatocytes
were isolated and further cultured as previously described [19].
Transient transfection of Alexander, SK-Hep-1 and HepG2 cells
was carried out with the Lipofectamine LTX and PLUS reagents
(Invitrogen). Cells were transfected with an empty vector (mock) or
plasmids containing FXR, RXR or both. In some cases, transfections
were carried out in combination with a plasmid containing an IR-1
response element upstream of a minimal promoter (minPr) and
the destabilized ﬁreﬂy luciferase (luc2CP) gene. After transfection
(48 h), cells were incubated with 5 μM cisplatin, 1 μM GW4064, or
with different concentrations of cisplatin or several toxic compounds,
with or without 1 μMGW4064, over 24 h, 48 h or 72 h, depending onthe parameter (cell viability, luciferase activity or mRNA levels) to be
measured.
2.4. Cell viability and luciferase activity
The amount of living cells was determined using the formazan test
(Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay,
Promega).
Promoter activation was followed by changes in the luciferase activ-
ity, measured with the Bright-Glo Luciferase Assay System (Promega)
on a LAS-4000 image reader (FujiFilm; TDI, Madrid, Spain). The inten-
sity of the signal was expressed as arbitrary units of luminescence
(light emission/10 min).
2.5. Gene expression analyses
Measurement of mRNA steady-state levels was carried out by
RT-QPCR as previously reported [17,20]. In brief, total RNA extraction
from cultured cells was performed as previously described [20]. RT
was carried out using the “SuperScript® VILO™ cDNA Synthesis Kit”
(Invitrogen). QPCR was performed using Amplitaq Gold polymerase
in an ABI Prism 7300 Sequence Detection System (Applied Biosystems,
Madrid, Spain) for single reactions to determine mRNA levels by
conventional RT-QPCR with SYBR® Green I detection, or using TLDAs
in an ABI Prism 7900HT Sequence Detection System (Applied
Biosystems) with TaqMan Mix detection. In all cases, the following
thermal conditions were used: a single cycle of 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. The primer
oligonucleotides for FXR and its target genes, and for the MOC genes
(Supplementary Table 2), together with their appropriate Taqman
probes to be included in the microﬂuidic cards, were designed and val-
idated by us or by Applied Biosystems (TLDAs) (data not shown).
Changes in the expression of the heterodimeric protein OSTα/β was
following by measuring the monomer with the highest expression
level in each cell type, i.e., OSTα in hepatocytes and OSTβ in Alexander
cells. 18S rRNAwas used as a quality-control check among samples and
groups. Double normalization of the results in each sample was carried
out with the values obtained for ACTB and GAPDH as previously
reported [17].
For protein detection by immunoﬂuorescence Alexander transfected
cells were ﬁxed and permeabilized in ice-coldmethanol, and nonspeciﬁc
binding sites were blocked by incubation with 5% fetal calf serum. Prep-
arationswere incubatedwith primary antibody from Invitrogen (anti-V5
against FXR-V5 diluted 1:200) and then for 1 hwith a 1:1000 dilution of
Alexa Fluor-488 anti-mouse secondary antibody, and 4,6-diamidino-
2-phenylindole (DAPI) to counterstain nuclei. Fluorescence staining
was visualized using a Leica TCS SP2 confocal microscope.
2.6. Bile acid measurement, in silico analysis and statistical methods
Bile acid concentrations in cell cultures were determined by
HPLC–MS/MS using a 6410 Triple Quad LC/MS (Agilent Technologies,
Santa Clara, California, USA), as previously reported [21].
In silico analysis for the search of putative FXR binding siteswas carried
out in the region of −3000 bp upstream of the start ATG codon. The
sequences detected in this region by SITAR analysis were compared with
target sequences of the identiﬁers as deﬁned in TRANSFAC® 7.0 database.
To calculate the statistical signiﬁcance of the differences between
groups, the paired or unpaired t-tests were used, as appropriate.
3. Results
3.1. FXR activation protects against cisplatin-induced toxicity
When human hepatocytes were placed in culture, a spontaneous
and progressive decrease in the expression of FXR was observed.
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of human liver over the ﬁrst 3–4 days in culture. Then steady state
was reached and maintained for up to, at least, 12 days (Supplemen-
tary Fig. 1). Experiments performed within this period revealed that
treatment with the FXR agonist GW4064 partly protected human
hepatocytes against cisplatin-induced toxicity (Fig. 1A).
To further investigate this effect the human hepatoma Alexander
cells, with negligible endogenous FXR steady state expression levels
(0.28% ± 0.06 of human liver) (Supplementary Fig. 2), were used as
experimental model. These cells were transiently transfected with
FXR. Prior to measuring FXR mRNA, the restriction enzyme DpnI,
which cuts methylated DNA, was used to digest the remaining intra-
cellular plasmids. A peak of FXR mRNAwas observed 48 h after trans-
fection (Supplementary Fig. 2), whenmost FXR protein was located in
the nucleus (Supplementary Fig. 2, inset). This time was therefore
used as the starting time to expose the cells to the compounds to be
tested. When the cells were transfected with the same amount of
DNA but divided into two plasmids containing either FXR or RXR,
the abundances of FXR mRNA and RXR mRNA 48 h after transfection
were 685% ± 45 and 490% ± 35 that of human liver, respectively.
Dose-dependent studies of cisplatin-induced cell death revealed
an improved survival of Alexander cells when they had been
transfected with FXR + RXR and were cultured in the presence of
1 μM GW4064 (Fig. 1B). Thus, the cisplatin IC50 was increased
5.8-fold under conditions of activated FXR (Fig. 2). Similar experi-
ments carried out in human liver adenocarcinoma SK-Hep-1 cells
also revealed a signiﬁcant FXR-mediated protection against cisplatin
toxicity (data not shown). Thus, the IC50 for cisplatin in these cellsFig. 1. Effect of FXR activation by 1 μM GW4064 on the sensitivity of human hepato-
cytes (A) and hepatoma Alexander cells expressing FXR (B) to cisplatin as measured
with the formazan test after incubation with the indicated concentrations of cisplatin
for 72 h. Alexander cells were transfected with plasmids containing FXR + RXR or
an empty vector (Mock) 48 h before adding GW4064 and cisplatin. Values are
expressed as means ± SD from 4 independent experiments performed in triplicate.
*, p b 0.05, as compared with Vehicle or Mock groups.was increased from 3.0 μM to 6.8 μM. In contrast, transfection with
RXR alone did not modify the sensitivity of Alexander or SK-Hep-1
cells to cisplatin (Fig. 2). Moreover, GW4064 had no effect on the sen-
sitivity of Alexander or SK-Hep-1 cells to cisplatin when the cells
were transfected with RXR either alone or with an empty vector.
3.2. Expression of genes involved in chemoresistance
To elucidate the relationship between FXR activation and enhanced
chemoresistance, GW4064-induced changes in the expression levels of
a set of 109 genes potentially involved in different MOC were investi-
gated (Table 1). Incubation with 1 μM GW4064 for 24 h resulted in a
signiﬁcant up-regulation of ﬁve genes involved in MOC-1b (ABCB4),
MOC-4 (TCEA2), MOC-5b (CCL14, CCL15 and KRT13), both in human he-
patocytes in primary culture (Fig. 3A) and Alexander cells transfected
with FXR + RXR (Fig. 3B). No effect on Alexander cells transfected
with an empty vector was found (data not shown).
3.3. Cisplatin-induced expression of FXR target genes
Since partial protection of the cells against cisplatin toxicity was
also seen in FXR transfected cells even in the absence of GW4064
(Fig. 2), we wondered whether endogenous bile acids could be
activating FXR in these cells. HPLC–MS/MS analysis revealed that,
under all the experimental conditions used here, bile acid levels in
Alexander cells were undetectable (data not shown).
A potential explanation would be the activation of FXR in response
to the toxicity of cisplatin. To elucidate this question, human hepato-
cytes were treated with cisplatin, which induced no signiﬁcant
change in the expression of FXR (Fig. 4). In contrast, cisplatin was
able to up-regulate several FXR target genes, such as BSEP, SHP,
OSTα and TCEA2 (Fig. 4).
To further analyze the effect of cisplatin on the FXR signaling path-
way, Alexander cells were transfected with FXR + RXR and treated
with cisplatin or GW4064 for 72 h, and the expression of FXR target
genes was determined. In mock cells, cisplatin, but not GW4064,
was already able to activate some, but not all, FXR target genes
assayed (Fig. 5A). In contrast, in FXR + RXR-transfected cells,
GW4064 induced a signiﬁcant effect on the expression of FXR target
genes (Fig. 5B). Surprisingly, cisplatin had a similar but weaker
FXR-dependent effect on these genes (Fig. 5B).
3.4. Cisplatin-induced activation of an IR-1 FXR-response element
The ability of cisplatin to directly or indirectly activate FXR, in the
absence of bile acids or GW4064, was then investigated by determin-
ing luciferase expression driven by an IR-1 consensus element inFig. 2. Effect of transfection with an empty vector (Mock), FXR, RXR or FXR + RXR with
and without activation with 1 μM GW4064 on the sensitivity to cisplatin expressed as
IC50 that was calculated from dose–response studies similar to these shown in Fig. 1B.
Values are expressed as mean ± SD from 4 independent experiments performed in
triplicate. *, p b 0.05, as compared with the Mock group.
Table 1
Genes included in the analysis of expression levels by RT-QPCR using TLDA or single reactions. Genes are classiﬁed on the bases of their role in mechanism of chemoresistance
(MOC) or the known sensitivity to FXR activation.
MOC-1a MOC-1b MOC-2 MOC-3 MOC-4 MOC-5a MOC-5b FXR Targets
Non-affected SLC10A1 ABCA2 CES1 DHFR ERCC1 AEG1 AKT1 CEBPB
SLC10A2 ABCA3 CES2 ESR2 DUT BAX BCL2 CYP3A4
SLCO2B1 ABCA6 CYP1A1 FRAP1 GADD45A BCL2L1 BIRC1 SLCO1B1
SLCO4A1 ABCA8 CYP1A2 KDR MLH1 BIRC2 BIRC4 SLCO1B3
SLC22A1 ABCB1 DPYD KIT MLH3 BIRC3 BIRC5
SLC22A2 ABCC1 GSTA1 mTOR MSH2 CDKN1A BIRC7
SLC22A4 ABCC2 GSTP1 PDGFRA MSH3 DIABLO BTG1
SLC22A5 ABCC3 TYMP TOP1 PMS1 FAS CASP8
SLC28A1 ABCC4 UGT1A TOP2A PMS2 PSMD9 CFLAR
SLC28A2 ABCC5 UMPS TYMS PRKDC TP53 EGFR
SLC28A3 ABCC6 UPP1 RAD51 JUN
SLC29A1 ABCC10 UPP2 RAD51AP1 MAPK1
SLC29A2 ABCC11 TCEA1 MYC
SLC31A1 ATP7A TCEA3 NFKB1
ATP7B UDG PIK3CG
MVP XPA RPL6
XPC SQSTM1
XRCC5
XRCC6
Up-regulated CCL14a ABCB11a
CCL15a ABCB4a
KRT13a
TCEA2a
a Genes whose expression was signiﬁcantly (p b 0.05) modiﬁed in human hepatoma Alexander cells transfected with FXR + RXR, in response to FXR activation by 1 μM
GW4064.
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transfected with FXR or FXR + RXR. In the absence of the IR-1
element, treatment with either cisplatin or GW4064 had no effect
on luciferase expression (Fig. 6A). In contrast, in the presence of the
IR-1 element both cisplatin and GW4064 (GW4064 > cisplatin)
induced luciferase expression (Fig. 6B).
3.5. Protection against genotoxicity
Since the mechanism of action of cisplatin is based on its damag-
ing interaction with DNA, we investigated whether, in absence of
FXR, cisplatin was able to activate several genes involved in MOC-4.
Indeed, p53 and p53-dependent proteins p21, GADD45 and FAS
were up-regulated by cisplatin in Alexander cells (Fig. 7). In contrast,
FXR + RXR transfection plus GW4064 did not up-regulate these
genes (Table 1). Finally, we investigated whether the protective effect
of FXR activation was speciﬁc for cisplatin or it was shared with other
genotoxic compounds. Transfection plus activation of FXR also
protected Alexander cells against other DNA damaging agents, such
as mitomycin C, doxorubicin and potassium dichromate, but not
against compounds without genotoxic activity, such as colchicine,
paclitaxel, acetaminophen, artesunate or sorafenib (Fig. 8).
4. Discussion
The present study revealed that activation of FXR with a typical
agonist, such as GW4064, elicited partial protection against the toxic
effect of cisplatin. Surprisingly, in the absence of GW4064 or other
typical agonists of this nuclear receptor, such as bile acids, the expres-
sion of FXR also protected the cells against cisplatin-induced toxicity.
This suggests that – directly or indirectly – cisplatin itself, and presum-
ably other toxic compounds, with genotoxic activity, are able to
activate the FXR pathway. Indeed, only when FXR was expressed,
cisplatin was able to activate luciferase expression driven by an IR-1response element. Although not impossible, the molecular structure
of cisplatin makes it unlikely that this drug would behave as a typical
FXR agonist. Accordingly, it could be speculated that themechanism of
cisplatin-induced FXR activation would be different from that of its
well-known ligands. Among the possibilities is FXR phosphorylation
by PKCζ and PKCα, which have been shown to activate FXR in the
absence of agonist [22,23]. Moreover, DNA damage induces the activa-
tion of PKC signaling pathways, resulting in an enhanced protein
kinase C activity able to phosphorylate FXR [24]. Whether other
DNA-damaging agents, but not other antitumor drugs, share this
mechanism of action resulting in FXR activation is not known, al-
though DNA-damaging agents, such as doxorubicin [25] and mitomy-
cin C [26] are known to also interact with this pathway.
An additional level of complexity was suggested by the ﬁndings
that cisplatin was able to activate the expression of several FXR target
genes, such as SHP and OSTβ, even in cells lacking FXR expression. In
contrast, cisplatin up-regulated BSEP and TCEA2 only when FXR was
expressed. The FXR-independent up-regulation of SHP has previously
been described to occur through the activation of p53 triggered by
DNA damage [27]. The reason for this overlap between the p53 and
FXR pathways is probably that both p53 and FXR share the MLL3
methyltransferase, which forms part of a coactivator complex able
to interact with multiple transcription factors [27]. Our results
support the concept that p53, a master sensor of DNA damage, may
be involved in an indirect activation of the transcription complex
able to enhance the expression of some FXR target genes.
Regarding the mechanism by which FXR is able to induce chemo-
protection, the expression of a large set of genes was analyzed. The
overexpression of ABC export pumps, belonging to MOC-1b, is one of
the major mechanisms accounting for the poor response of tumors to
anticancer drugs. However, we only found changes in the expression of
BSEP and MDR3. BSEP is a well-known target of FXR whose main func-
tion is the transport of bile acids into the canalicular lumen [28]. This
pump is also able to transport some anticancer compounds, such as
Fig. 3. Effect of FXR activation on the expression of genes involved in chemoresistance
in human hepatocytes in primary culture (A) and in human hepatoma Alexander cells
transfected with FXR + RXR (B). Cells were treated with 1 μM GW4064 for 24 h be-
fore gene expression was measured by RT-QPCR. Results, expressed as fold induction
by comparing with basal conditions in the absence of GW4064, are means ± SD
from 4 independent experiments performed in triplicate. *, p b 0.05, as compared
with untreated control cells. MOC, type of mechanism of chemoresistance.
Fig. 5. Time-course of the effect of cisplatin or GW4064 on the amount mRNA for FXR
taget genes in human hepatoma Alexander cells transfected with an empty vector
(Mock) (A) or plasmids containing FXR and RXR (B) 48 h before adding the drug
(5 μM cisplatin or 1 μM GW4064) or only DMSO (Vehicle). Values are expressed as
means ± SD from 4 independent experiments performed in triplicate. *, p b 0.05,
compared with the Vehicle group; †, p b 0.05, comparing Cisplatin with GW4064.
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is mainly expressed in the canalicular membrane of the hepatocytes,
where it plays a role as phospholipid translocase [30], but its relevance
in chemoresistance is poorly understood. MDR3 is overexpressed in
K562 cells resistant to doxorubicin [31], one of the compoundswhose ef-
ﬁcacy was found to be reduced when FXR was expressed and activated.
MRP2 is particularly important in the chemoresistance to cisplatin [1].
Thus, MRP2 expression levels have been correlated with the sensitivity
of several cell lines to cisplatin [32]. We have previously described
that cisplatin treatment is able to induce MRP2 expression in colon
cancer cells [16]. Furthermore, we have reported that FXR-dependentFig. 4. Cisplatin-induced changes in the expression of FXR target genes in human hepato-
cytes, as measured by RT-QPCR, in response to incubation with 5 μM cisplatin or 1 μM
GW4064 for 24 h. Values are expressed as means ± SD from 4 independent experiments
performed in triplicate. *, p b 0.05, as comparedwith cells treated onlywithDMSO (Vehicle).overexpression of BCRP may also be involved in the chemoresistance of
colon cancer to cisplatin [16]. However, in liver cells, no signiﬁcant
changes in the expression ofMRP2 or BCRP in response to FXR activation
have been found.
Although MOC-2 and MOC-3 include FXR target genes, such as
CEBPB and CYP3A4, no changes in the expression of these genes in
response to FXR activation was found. In contrast, interesting results
regarding MOC-4 were obtained. The expression of TCEA2, recently
reported as an FXR target gene [33], was induced after the activation
of FXR. The protein encoded by this gene, TFIIS, is an elongation factor
involved in the transcription-coupled DNA repair mechanism and has
previously been associated with chemoresistance to cisplatin [34].
The FXR-mediated up-regulation of TCEA2, but not of TCEA1 or
TCEA3, found in the present study suggest that only the isoform 2 of
this protein is probably involved in the enhanced chemoresistance
to agents with known ability to induce DNA damage, such as doxoru-
bicin, mitomycin C, cisplatin and potassium dichromate [35].
Changes in the expression of genes belonging to MOC-5 could ac-
count for the reduced sensitivity to mitomycin C, whose mechanism
of action includes the up-regulation of caspase-8, which leads to apo-
ptosis [36]. Since KRT13 has anti-apoptotic properties [37], the
up-regulation of this protein may result in enhanced protection
against the toxicity of mitomycin C, and other pro-apoptotic drugs
used in this study. Although the mechanism of action of artesunate
involves the up-regulation of a large number of pro-apoptotic genes
and the down-regulation of others [38], we have found no changes
in the expression of these genes. Thus, the absence of FXR-induced
Fig. 6. Cisplatin-induced activation of the FXR-response element IR-1. Human
hepatoblastoma HepG2 and hepatoma Alexander cells were transfected with a plasmid
containing either a minimal promoter (minPr) controlling the expression of the
destabilized ﬁreﬂy luciferase (luc2CP), used here as a reporter gen, alone (A) or in combi-
nation with an IR-1 response element located upstream of the minPr (B). In addition
Alexander cells were transfected with an empty vector (Mock) or plasmids containing
FXR and RXR. The drug (5 μM cisplatin or 1 μM GW4064) or only DMSO (Vehicle) were
added 48 h after transfection and the cells were incubated for 4 h before luminiscence
was measured. Values are expressed as means ± SD from 4 independent experiments
performed in triplicate. *, p b 0.05, comparedwith the Vehicle group; †, p b 0.05, compar-
ing Cisplatin with GW4064.
Fig. 7. Time-course of the effect of cisplatin on the amount mRNA for p53 and p53-
dependent genes in human hepatoma Alexander cells transfected with an empty vector
48 h before adding 5 μM cisplatin or only DMSO (Vehicle). Values are expressed
as means ± SD from 4 independent experiments performed in triplicate. *, p b 0.05,
compared with the Vehicle group.
Fig. 8. Protective effect of FXR activation against genotoxic compounds. Viability of cells
transfected with FXR + RXR or an empty vector and treated with 5 μM colchicine, 10 nM
paclitaxel, 1.5 mM acetaminophen, 20 μM artesunate, 5 μM sorafenib, 50 μM cisplatin,
2.5 μMmitomycin C, 250 nM doxorubicin or 2.5 μM potassium dichromate (K2Cr2O7) with
orwithout 1 μMGW4064 for 72 h. Values are expressed asmean ± SD from 4 independent
experiments performed in triplicate. *, p b 0.05, as compared with the Mock group.
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fect on the proapoptotic/survival balance in our experimental setting.
Regarding the FXR-dependent enhanced expression of CCL14 and
CCL15, although chemokines are involved in angiogenesis and cell
proliferation, migration, invasion and metastasis [39] their role in
the chemoprotective response to FXR remains unclear.
Data obtained by other groups support the hypothesis that FXR
can be involved in the regulation of some of the 5 genes (ABCB4,
TCEA2, CCL14, CCL15 and KRT13) whose expression we have
found here to be sensitive to FXR activation. Thus, Huang et al. have
shown that the FXR/RXR heterodimer binds speciﬁcally to the IR-1
element in the human ABCB4 promoter [13]. Moreover, Cuesta et al.,
have recently shown that the TCEA2 gene is also regulated by FXR
[33]. The fact that FXR bound to a conserved regulatory element in
the proximal human KRT13 promoter has also been described [37].
Moreover, in silico analysis in the search of potential sites for
FXR-mediated regulation in the promoter region of these 5 genes
has revealed several putative binding sites for FXR in all of
them (Table 2), whose actual role in chemoresistance remain to be
elucidated.
5. Conclusions
In conclusion, these results indicate that the ligand-dependent
and independent activation of FXR and/or its signaling pathway is
involved in the chemoprotective response of liver cells. This is due
in part to changes in the expression of several genes (ABCB4, TCEA2,
CCL14, CCL15 and KRT13) accounting for different MOC, mainly
these involved in drug efﬂux (MOC-1b), DNA repair (MOC-4) and
cell survival (MOC-5b). Moreover, this characteristic is shared
by healthy and tumor cells, and hence may play an important role
in enhancing the chemoprotection of healthy hepatocytes against
genotoxic compounds and reducing the response of liver tumor
cells to certain pharmacological treatments.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.05.006.
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Table 2
Putative binding sites for FXR in the promoter regions of chemoresistance genes.
Gene Position Sequence 5′-3′ (Sitar)a Comparisonb Sense Mismatches TRANSFAC Data Identiﬁer
Target sequencec
ABCB4 −2757 GGGTGAATAAAAA GGGTGAnTAAaaa N 3 GGGTGAnTAACCT IBABP
−2501 AGGGCATTAATTC GAaTTAnTGcCCT R 2 GAGTTAnTGACCT SHP
−983 AGGGCACTGGACT AGGgCAnTGgaCT N 3 AGGTCAnTGACCT Consensus
TCEA2 −2843 AGGACCCTGACCA AGGaCcnTGACCa N 3 AGGTCAnTGACCT Consensus
−2299 TGGTCTCAAACTC GAGTTtnaGACCa R 3 GAGTTAnTGACCT SHP
−1816 GATCTCCTGACCT GAtcTcnTGACCT N 3 GAGTTAnTGACCT SHP
−1682 GAACTCCTGACCT GAacTcnTGACCT N 3 GAGTTAnTGACCT SHP
−1364 GAACTCCTGACCT GAacTcnTGACCT N 3 GAGTTAnTGACCT SHP
−1350 AGGTGATCCACCC GGGTGanTcACCT R 2 GGGTGAnTAACCT IBABP
−1155 AGTTCGTTGGCCT AGtTCgnTGgCCT N 3 AGGTCAnTGACCT Consensus
−931 ATGTCAATGAACA AtGTCAnTGAaCa N 3 AGGTCAnTGACCT Consensus
CCL14 −2474 AGGTTTATGTCCT AGGTttnTGtCCT N 3 AGGTCAnTGACCT Consensus
−2337 AGGTCTCTAATTA tAaTTAnaGACCT R 3 GAGTTAnTGACCT SHP
−2256 AGTTCTGAGACCT AGtTCtnaGACCT N 3 AGGTCAnTGACCT Consensus
−1261 AGGGCACTAAGCT AGGgCAnTaAgCT N 3 AGGTCAnTGACCT Consensus
CCL15 −2619 AGGTGAATTTCCC GGGaaAnTcACCT R 3 GGGTGAnTAACCT IBABP
−2134 TGGTCTGGAACTC GAGTTcnaGACCa R 3 GAGTTAnTGACCT SHP
−1830 GAGTTAATGGGTT GAGTTAnTGggtT N 3 GAGTTAnTGACCT SHP
−1312 AGGTGGATCACCT aGGTGgnTcACCT N 3 GGGTGAnTAACCT IBABP
−1291 GAGTTCGAGACCA GAGTTcnaGACCa N 3 GAGTTAnTGACCT SHP
−794 TGGTATGTGACCT tGGTatnTGACCT N 3 AGGTCAnTGACCT Consensus
−550 CGGTCTCTCACTC GAGTgAnaGACCg R 3 GAGTTAnTGACCT SHP
−365 AAGATAGTCCCCC GGGgGAnTAtCtT R 3 GGGTGAnTAACCT IBABP
−327 AGATTAATCTCCT aGGaGAnTAAtCT R 3 GGGTGAnTAACCT IBABP
KRT13 −2954 ATGTCAGAAACTG cAGTTtnTGACaT R 3 GAGTTAnTGACCT SHP
−2103 GGCTGAATCACCC GGcTGAnTcACCc N 3 GGGTGAnTAACCT IBABP
−1620 AGGTCCTTTTCTC GAGaaAngGACCT R 3 GAGTTAnTGACCT SHP
−1082 AGGTAATTGACTG cAGTcAnTtACCT R 3 GAGTTAnTGACCT SHP
In silico analysis for the search of putative FXR binding sites was carried out in the region of−3000 bp upstream of the start ATG codon. The sequences detected in this region by
SITAR analysis (a) were compared (b) with target sequences (c) of the identiﬁers as deﬁned in TRANSFAC® 7.0 database. The cut-off value was ﬁxed at 3 mismatches. N, normal
sense; R, reverse sense.
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